Radiopharmaceutical therapy has already transformed care for neuroendocrine tumors and prostate cancer, but other tumor types still lack targeted treatment options. A new approach could change this.
Prof. Johanna Joyce has begun her two-year term as President of the European Association for Cancer Research (EACR), a global community of scientists and clinicians dedicated to advancing the scientific understanding of cancer and its application to improve patient care.
A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.
Obesity may change how early-stage breast cancer becomes invasive, according to a new study. The findings could help improve physicians’ ability to predict and treat the disease.
Researchers are developing nanozymes to improve treatment of aggressive brain tumours. The tiny particles can be activated by near-infrared light and applied directly during surgery.
Not all precancerous lesions will develop into tumours, yet the majority are treated as if they were already breast cancer. A new marker could help identify the relevant cases and avoid overtreatment.
Researchers have taken an early but promising step toward a cancer therapy that targets and destroys tumor cells with high precision, using a variant of the DNA editing tool CRISPR.
For a young adult, a cancer diagnosis hits different: a more aggressive disease course, greater disruptive potential, longer survivorship. Yet most healthcare institutions seem poorly prepared for this growing patient group. A plenary session at the NCCN 2026 Annual Conference examined a striking shift in modern oncology: the rising incidence of cancer in adolescents and young adults (AYA).
A multidisciplinary team of pathologists, oncologists and biologists has discovered a new biomarker to determine whether immunotherapy may work in people with colon and rectal cancer.
Researchers have developed a new MRI-based method that enables objective quantification of the growth of the most aggressive brain tumours, particularly glioblastoma.
Patient-derived organoids (PDOs), or tumoroids, for pediatric brain cancer show promise in helping researchers find new drugs and better understand the different responses of the tumor.
Researchers discovered that pineoblastoma, retinoblastoma and medulloblastoma – severe brain tumours in children that appear to be completely different – actually arise from the same type of cell.
A research team led by the University of Waterloo is developing a novel tool to treat cancer by engineering hungry bacteria to literally eat tumours from the inside out.
Although tumours may at first shrink under therapy, they often regrow or even become resistant. A new study suggests switching to a second treatment while the tumour is still responding to the first.
Clues in the CSF: Researchers have developed the first high-precision method that can theoretically diagnose common brain tumors in children and adolescents without surgery.
Not all cancer mutations are equal: new research shows that a single mutation hotspot can generate a rich diversity of tumour behaviours. This could lead to more personalised cancer treatments.
Immunotherapy has been hailed as a breakthrough in cancer treatment. But new research reveals: under sustained treatment pressure, cancer does not simply weaken — it adapts, learns, and fights back.
To soften up tumors prior to cancer chemotherapy, a team of researchers paired high-frequency ultrasound waves with a type of sound-responsive particle to reduce the protein content of the tumors.
A novel AI-based method can distinguish between progressive brain tumours and radiotherapy-induced necrosis on advanced MRI. This could help clinicians more accurately identify and treat the issues.
